Acrodermatitis Chronica Atrophicans
- Author: Bozena Chodynicka, MD; Chief Editor: Dirk M Elston, MD more...
Background
Acrodermatitis chronica atrophicans (ACA) is the third or late stage of European Lyme borreliosis (LB).[1, 2] This unusual, progressive, fibrosing skin process is due to the effect of continuing active infection with Borrelia afzelii. Buchwald first delineated it in 1883[3] ; Herxheimer and Hartmann described it in 1902 as a tissue paper–like cutaneous atrophy.[4] It is evident on the extremities, particularly on the extensor surfaces, beginning with an inflammatory stage with bluish red discoloration and cutaneous swelling and concluding several months or years later with an atrophic phase. Sclerotic skin plaques may also develop. Physicians should use serologic and histologic examination to confirm this diagnosis.
Note the images below.
A 73-year-old female farmer with a cutaneous plaque on the sole of her right foot lasting for 6 months that, in the meantime, had extended onto the dorsum of her foot, her right leg, and the lower part of her right thigh. Infection of Borrelia burgdorferi was diagnosed with enzyme-linked immunosorbent assay, and acrodermatitis chronica atrophicans was confirmed histologically. 
A 50-year-old male farmer was examined for cutaneous plaques on the dorsal side of his right hand lasting for 8 months that, in the meantime, had extended onto his right forearm and arm and had also developed on his right thigh. The patient complained of muscular weakness related to his right upper limb and periodic arthralgia. The neurologic examination demonstrated signs of right brachial plexus damage, confirmed by electromyography. Borrelia burgdorferi infection was diagnosed with enzyme-linked immunosorbent assay, indirect immunofluorescence assay (titer: 1:1,024), and Western blot. Histologic examination confirmed the diagnosis of acrodermatitis chronica atrophicans. 
A 68-year-old woman with a history of untreated erythema migrans on her left thigh 2 years previously. Ten months later, the plaque extended over the skin of her left buttock and became bluish with signs of livedo racemosa. Her forearms and breast were also involved. Borrelia burgdorferi infection was diagnosed with indirect immunofluorescence assay (1:4,096) and Western blot. Acrodermatitis chronica atrophicans was confirmed histologically. Because of intrathecal production of specific antibodies, diagnosis of asymptomatic neuroborreliosis was established. 
The livedo racemosa and acrodermatitis chronica atrophicans lesions on the left thigh and buttock before treatment. 
The inflammatory phase of acrodermatitis chronica atrophicans can be seen with rosacea lesions on the cheek, the forehead, and the nose. Pathophysiology
B afzelii is the predominant, but may not be the exclusive, etiologic agent of acrodermatitis chronica atrophicans. Another genospecies of the Borrelia burgdorferi sensu lato complex, Borrelia garinii, has also been detected.
Acrodermatitis chronica atrophicans is the only form of Lyme borreliosis in which no spontaneous remission occurs. Its pathophysiology is not yet fully understood. Acrodermatitis chronica atrophicans appears to be associated with long-term persistence of Borrelia organisms in the skin; several nonspecific reactions together with a specific immune response may contribute to its manifestations.
The persistence of the spirochetes despite a marked cutaneous T-cell infiltration and high serum antibody titers may be connected with resistance of the pathogen to the complement system; the ability to escape to immunologically protected sites (eg, endothelial cells, fibroblasts); and the ability to change antigens, which may lead to an inappropriate immune response. Lack of protective antibodies, with a narrow antibody spectrum and a weak cellular response with down-regulation of major histocompatibility system class II molecules on Langerhans cells, has been observed in patients with Lyme borreliosis.
A restricted pattern of cytokine expression in acrodermatitis chronica atrophicans, including the lack of interferon-gamma, may contribute to its chronicity. Cross-reactive antibody responses could take part in autoimmune damage, but whether autoimmune reactions play any role in the pathogenesis of the disease is unclear. The pathogenic mechanism of atrophic skin changes has also not been clarified. Perhaps periarticular regions are favorite sites because of reduced acral skin temperatures or reduced oxygen pressure.
Epidemiology
Frequency
United States
The occurrence of acrodermatitis chronica atrophicans is connected with the ecology of Lyme borreliosis, which varies in different geographical regions of the world.
Despite a high incidence of Lyme borreliosis in the United States (varying from 95 cases per 100,000 population in Connecticut to 1250 cases per 100,000 population in Nantucket County, Massachusetts [1996 data]), acrodermatitis chronica atrophicans is not seen in the United States, except in a few European immigrants.[5]
International
The occurrence of acrodermatitis chronica atrophicans is connected with the ecology of Lyme borreliosis, which varies in different geographical regions of the world.
Ixodes scapularis, Ixodes pacificus, and 4 other tick species distributed in North America transmit B burgdorferi sensu stricto, causing EM and Lyme borreliosis arthritis.
Tick vectors of B afzelii, the main etiologic agent of acrodermatitis chronica atrophicans (and erythema migrans [EM]), are Ixodes ricinus, Ixodes hexagonus, and Ixodes persulcatus distributed in western and central Europe and in far eastern Europe and Asia. Almost all of these hard tick species may also transmit B garinii, a causative agent of EM and neurologic symptoms of Lyme borreliosis.
In Europe, Lyme borreliosis with all its dermatologic manifestations occurs in almost all countries, predominantly in the central part of the continent. The annual incidence per 100,000 population varies from 16 cases in France to 120 cases in northeastern Poland and Slovenia and to 130 cases in Austria (1995 data).[6]
The frequency of acrodermatitis chronica atrophicans is about 1-10% of all European patients with Lyme borreliosis, varying according to the region of the population sampled. Among the group of patients with skin manifestations of Lyme borreliosis observed in Vienna, the ratio of the number of EM cases to acrodermatitis chronica atrophicans cases and to Borrelia lymphocytoma (BL) cases was 30:3:1. This ratio is 170:5:1 in the authors' as-yet-unpublished studies (provided in the group of patients with Lyme borreliosis in northeastern Poland).
Because the clinical diagnosis of acrodermatitis chronica atrophicans is much more difficult than that of EM or BL, the condition is often underdiagnosed, and, in fact, the ratio of EM cases to acrodermatitis chronica atrophicans cases may be higher. The total number of cases could increase with increasing frequency of untreated European Lyme borreliosis. Acrodermatitis chronica atrophicans is probably the most common late and chronic manifestation of the borreliosis in European patients with Lyme disease.
A Bulgarian survey found that borrelial lymphocytoma and acrodermatitis chronica atrophicans were rare (0.3%).[7]
Mortality/Morbidity
The course of acrodermatitis chronica atrophicans is long-standing, lasting from a few to several years, and it leads to extensive flaccid atrophy of the skin and, in some patients, to the limitation of upper and lower limb joint mobility.
Chronic, difficult-to-treat ulcerations of atrophic skin may develop after minor trauma. Malignant degeneration has rarely been observed; one should not consider acrodermatitis chronica atrophicans to be a precancerous disorder.
The general status of patients with acrodermatitis chronica atrophicans remains good, though they may experience neurologic and/or rheumatologic signs and symptoms.
Race
Acrodermatitis chronica atrophicans is not limited to any one nationality or race. It is much more frequent in whites than in other races, probably because of a far higher exposure to ticks transmitting B afzelii.
Sex
More than two thirds of patients with acrodermatitis chronica atrophicans are women. Among the authors' 19 patients, only 5 were men.[8]
Age
Acrodermatitis chronica atrophicans can occur in any age group, but it is most frequent in adults, usually in their 40s or 50s. The youngest of the authors' patients was 26 years; the oldest was 73 years.[8] The mean age of the female group was 54.3 ± 12.8 years; the mean age of the male group was 46.2 ± 6.5 years. Acrodermatitis chronica atrophicans is rare in adolescents; however, it has been observed in children. A case in a 15-year-old girl was reported by Zalaudek et al in 2005.[9]
Bhate C, Schwartz RA. Lyme disease: Part I. Advances and perspectives. J Am Acad Dermatol. Apr 2011;64(4):619-36; quiz 637-8. [Medline].
Bhate C, Schwartz RA. Lyme disease: Part II. Management and prevention. J Am Acad Dermatol. Apr 2011;64(4):639-53; quiz 654, 653. [Medline].
Buchwald A. Ein Fall von diffuser idiopathischer Haut-Atrophie. Vrtljschr Derm. 1883;10:553-6.
Herxheimer K, Hartmann K. Ueber Acrodermatitis chronica atrophicans. Arch f Dermatol u Syph (Wien). 1902;61:57-76.
Smetanick MT, Zellis SL, Ermolovich T. Acrodermatitis chronica atrophicans: a case report and review of the literature. Cutis. May 2010;85(5):247-52. [Medline].
Aberer E. Country report - Austria. Report of WHO Workshop on Lyme Borreliosis Diagnosis and Surveillance, Warsaw. Warsaw, Poland: World Health Organization; 1995.
Christova I, Komitova R. Clinical and epidemiological features of Lyme borreliosis in Bulgaria. Wien Klin Wochenschr. Jan 31 2004;116(1-2):42-6. [Medline].
Flisiak I, Schwartz RA, Chodynicka B. Clinical features and specific immunological response to Borrelia afzelii in patients with acrodermatitis chronica atrophicans. J Med. 1999;30(3-4):267-78. [Medline].
Zalaudek I, Leinweber B, Kerl H, Mullegger RR. Acrodermatitis chronica atrophicans in a 15-year-old girl misdiagnosed as venous insufficiency for 6 years. J Am Acad Dermatol. 2005;52:1091-4. [Medline].
Danz B, Kreft B, Radant K, Marsch WCh, Fiedler E. Skin-coloured facial oedema as an initial manifestation of acrodermatitis chronica atrophicans. J Eur Acad Dermatol Venereol. Jun 2008;22(6):751-3. [Medline].
Mullegger RR, Glatz M. Skin manifestations of lyme borreliosis: diagnosis and management. Am J Clin Dermatol. 2008;9(6):355-68. [Medline].
Maraspin V, Ogrinc K, Ružic-Sabljic E, Lotric-Furlan S, Strle F. Isolation of Borrelia burgdorferi sensu lato from blood of adult patients with borrelial lymphocytoma, Lyme neuroborreliosis, Lyme arthritis and acrodermatitis chronica atrophicans. Infection. Feb 2011;39(1):35-40. [Medline].
Andres C, Ziai M, Bruckbauer H, Ring J, Hofmann H. Acrodermatitis chronica atrophicans in two children. Int J Dermatol. Feb 2010;49(2):180-3. [Medline].
Leverkus M, Finner AM, Pokrywka A, Franke I, Gollnick H. Metastatic squamous cell carcinoma of the ankle in long-standing untreated acrodermatitis chronica atrophicans. Dermatology. 2008;217(3):215-8. [Medline].
Braun-Falco O, Plewig G, Wolff HH. Dermatology. 2nd ed. Berlin, Germany: Springer-Verlag; 2000:188-90.
Chodynicka B, Flisiak I. Treatment and prophylaxis of Lyme disease. Postepy Dermatol (Poznan). 2000;17:43-52.
Chodynicka B, Flisiak I, Lukaszuk C, Bulhak V. [Late consequences of untreated lyme borreliosis]. Przegl Epidemiol. 1997;51(4):445-9. [Medline].
Print
